NCYM is upregulated by IncUSMycN and modulates N-Myc expression

PEI Y. LIU1, BERNARD ATMADIBRATA1, SUJANNA MONDAL1, ANDREW E. TEE1 and TAO LIU1,2

1Children's Cancer Institute Australia for Medical Research, Randwick, Sydney, NSW 2031; 2Centre for Childhood Cancer Research, UNSW Australia, Sydney, NSW 2052, Australia

Received August 8, 2016; Accepted September 27, 2016

DOI: 10.3892/ijo.2016.3730

Correspondence to: Dr Tao Liu, Children's Cancer Institute Australia for Medical Research, Randwick, Sydney, NSW 2031, Australia
E-mail: tliu@ccia.unsw.edu.au

Key words: neuroblastoma, NCYM, N-Myc, IncUSMycN

Abstract. Neuroblastoma is the most common solid tumor in early childhood. Patients with neuroblastoma due to the amplification of a 130-kb genomic DNA region containing the MYCN, MYCN antisense NCYM and IncUSMycN genes show poor prognosis. BET bromodomain inhibitors show anticancer efficacy against neuroblastoma partly by reducing MYCN gene transcription and N-Myc mRNA and protein expression. We have previously shown that the long nongcoding RNA IncUSMycN upregulates N-Myc mRNA expression by binding to the RNA-binding protein NonO. In this study, we found that IncUSMycN upregulated NCYM expression, and knocking-down IncUSMycN reduced histone H3 lysine 4 trimethylation, a marker for active gene transcription, at the NCYM gene promoter. NCYM upregulated N-Myc mRNA expression, NCYM RNA formed a complex with NonO protein, and knocking down NCYM expression reduced neuroblastoma cell proliferation. Importantly, treatment with BET bromodomain inhibitors reduced NCYM expression. In human neuroblastoma patients, high levels of NCYM expression in tumor tissues correlated with high levels of N-Myc, NonO and IncUSMycN expression as well as poor patient prognosis. Taken together, our findings suggest that IncUSMycN upregulates NCYM expression by activating its gene transcription, and that NCYM RNA upregulates N-Myc mRNA expression by binding to NonO. Our findings also provide further evidence for the application of BET bromodomain inhibitors for the therapy of neuroblastoma characterized by MYCN/NCYM gene locus amplification.

Introduction

Neuroblastoma is the most common solid tumor in children less than 5 years old, and is derived from primordial neural crest cells that eventually reside in the sympathetic nervous system (1,2). Amplification of a 130 kb core genomic DNA region containing the MYCN oncogene, the MYCN antisense NCYM gene and the long non-coding RNA IncUSMycN gene, occurs in more than a quarter of human neuroblastoma tissues (3). More than 70% of patients with neuroblastoma associated with the amplification of the 130 kb core genomic DNA region die of the disease in spite of current intensive multimodal therapies (4,5).

The MYCN oncogene encodes the transcription factor N-Myc which plays important roles in cell proliferation and differentiation during embryonic development (6), and induces neuroblastoma initiation and progression by regulating target gene expression (7).

Long non-coding RNAs are transcripts longer than 200 nucleotides without protein-coding potential, and can be divided into five different classes according to their gene position relevant to neighbouring protein-coding genes: sense, antisense, bidirectional, intronic and intergenic (8,9). Long non-coding RNAs have recently emerged as important regulators of gene transcription, malignant transformation, tumor initiation, progression and metastasis (10,11). For example, lincRNA-p21 is activated by the tumor suppressor p53, represses the transcription of the genes that interfere with apoptosis, and plays a critical role in p53-mediated apoptosis (12). The long non-coding RNA NORAD is induced after DNA damage, and maintains genomic stability by sequestering PUMILIO proteins (13). We have recently shown that the long non-coding RNA IncUSMycN increases N-Myc mRNA expression by interacting with the RNA-binding protein NonO (14).

While N-Myc has been extensively studied, the function of the antisense NCYM gene did not attract research until recently. NCYM has been shown to stabilize N-Myc protein by inhibiting the activity of GSK3β, a kinase that promotes N-Myc protein degradation (15), and to promote calpain-mediated Myc-nick production in human neuroblastoma cells (16). In addition, NCYM plays an essential role in neuroblastoma cell metastasis (15). In this study, we examined how NCYM gene expression was regulated, whether NCYM regulated the expression of its neighbouring protein-coding gene MYCN, and whether a high level of NCYM expression in human neuroblastoma tissues was a marker for poor patient survival.
Materials and methods

Cell culture. Neuroblastoma BE(2)-C cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. Kelly cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal calf serum and 1% L-glutamine. All cell lines were maintained in a humidified incubator at 37˚C and 5% CO₂ in air. The identity of all cell lines was authenticated by small tandem repeat profiling conducted at the Garvan Institute or Cellbank Australia.

siRNA transient transfection. Tumor cells were transfected with siRNAs using Lipofectamine 2000 reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Pre-designed control siRNA and siRNA specifically targeting NCYM or N-Myc were purchased from Qiagen (Qiagen, Hamburg, Germany), and the lncUSMycN siRNAs were custom synthesized by Dharmacon (Lafayette, CO, USA) (14,17).

Quantitative real-time RT-PCR. NCYM and N-Myc expression was examined by quantitative real-time RT-PCR with Power SYBR Green Master Mix (Life Technologies, Grand Island, NY, USA) as a fluorescent dye on ABI-7900 (Applied Biosystems, Grand Island, NY, USA) according to the manufacturer's instructions and as we described previously (18,19). The expression of genes of interest was determined after normalisation according the expression level of the housekeeping gene β-actin in the total RNA samples.

Immunoblotting. Cells were lysed, protein was extracted and separated by gel electrophoresis. After western transfer, membranes were probed with an anti-N-Myc (1:2,000) (Santa Cruz Biotech, Santa Cruz, CA, USA) antibody followed by a horseradish peroxidase-conjugated anti-mouse (1:10,000) antibody (Santa Cruz Biotech). Protein bands were visualized with SuperSignal (Pierce, Rockford, IL, USA). Finally, the membranes were re-probed with an anti-actin antibody (1:10,000; Sigma, St. Louis, MO, USA) as loading controls.

Cell proliferation assays. Cell proliferation was examined with Alamar blue assays as we described previously (20). Briefly, cells were plated into 96-well plates and transfected with various siRNAs. Ninety-one hours later, cells were incubated with Alamar blue (Invitrogen) for five hours, and plates were read on a micro-plate reader at 570/595 nm. Results were calculated according to the readings (optical density absorbance units) and expressed as percentage changes in cell numbers.

RNA immunoprecipitation assays. RNA immunoprecipitation assays were performed using Magna RIP kit from Merck Millipore according to the manufacturer's instructions (Merck Millipore, Billerica, MA, USA), with 5 µg of control IgG or anti-NonO antibody for immunoprecipitation and primers targeting NCYM or the negative control U1 RNA for RT-PCR (14).

Patient tumor sample analyses. NCYM, N-Myc, NonO and lncUSMycN expression in neuroblastoma tissues was analysed in 88 (Versteeg dataset) and 476 (Kocak dataset) human neuroblastoma samples in the publicly available gene expression databases (http://r2.amc.nl). Clinical information for the 88 patients in the Versteeg dataset was directly
Correlation between NCYM expression and N-Myc, NonO and lncUSMycN expression in human neuroblastoma tissues was examined with Pearson's correlation. For patient prognosis studies, overall survival was defined as the time from diagnosis until death, or otherwise as the time until last contact. The patient cohort was dichotomized into two groups (low versus high NCYM expression). Survival analyses were performed according to the method of Kaplan and Meier and comparisons of survival curves were made using two-sided log-rank tests (23).

Statistical analyses. All data for statistical analysis were calculated as mean ± standard error. Differences were analyzed for significance using two-sided unpaired t-test for two groups, or multiple comparison one-way analysis of variance (ANOVA) for more than two groups. A probability value of ≤0.05 was considered significant.

Results

The long non-coding RNA IncUSMycN upregulates NCYM expression by inducing its gene transcription. The IncUSMycN, NCYM and MYCN genes are within the 130 kb core genomic DNA region amplified in a quarter of human neuroblastoma tissues (3). As long non-coding RNAs are well-known to upregulate the expression of neighboring genes in cis (24), we investigated whether IncUSMycN modulated NCYM gene expression. BE(2)-C and Kelly neuroblastoma cells were transfected with control siRNA or two independent siRNAs targeting different regions of IncUSMycN. The IncUSMycN siRNAs had been previously validated to knock down IncUSMycN RNA expression in BE(2)-C and Kelly cells (14). As shown in Fig. 1A, transfection with IncUSMycN siRNAs...
LIU et al: NCYM UPREGULATES N-Myc EXPRESSION

significantly reduced NCYM RNA expression in the MYCN oncogene-amplified BE(2)-C and Kelly neuroblastoma cells.

To understand whether lncUSMycN upregulated NCYM expression through activating NCYM gene transcription, we performed chromatin immunoprecipitation (ChIP) assays with a control antibody (Ab) or an antibody against trimethylated histone H3 lysine 4 (H3K4me3), a marker for active gene transcription. As shown in Fig. 1B and C, the ChIP assays showed that knocking down lncUSMycN expression with siRNAs reduced histone H3K4 trimethylation at the NCYM gene promoter (intron 1). Taken together, the data suggest that lncUSMycN upregulates NCYM expression by enhancing its gene transcription.

**NCYM upregulates N-Myc expression and induces neuroblastoma cell proliferation.** As the NCYM gene is antisense to the MYCN oncogene, we examined whether NCYM regulated N-Myc expression. BE(2)-C and Kelly cells were transfected with two independent siRNAs targeting different regions of NCYM RNA or a control siRNA for 48 h. As shown in Fig. 2A, transfection with NCYM siRNAs efficiently reduced NCYM expression. RT-PCR analysis showed that knocking down NCYM expression with siRNAs reduced N-Myc mRNA expression (Fig. 2B), and immunoblot analysis showed that knocking down NCYM expression also reduced N-Myc protein expression (Fig. 2C). Consistent with the RT-PCR data, the reduction in N-Myc protein expression by NCYM siRNA-1 was weaker than NCYM siRNA-2, indicating variation in the efficacy of NCYM siRNA-1 and NCYM siRNA-2.

As N-Myc is well-known to induce neuroblastoma cell proliferation, we performed Alamar blue cell proliferation assays in BE(2)-C and Kelly cells after transfection with control siRNA, NCYM siRNA-1 or NCYM siRNA-2 for 48 h. Alamar blue assays showed that knocking down NCYM expression with siRNAs reduced the number of neuroblastoma cells (Fig. 2D). Taken together, these data suggest that NCYM

**Figure 3.** NCYM RNA binds to the RNA-binding protein NonO. RNA immunoprecipitation assays were performed with a control or an anti-NonO antibody in Kelly cells. RNA samples immunoprecipitated by the control IgG or the anti-NonO antibody were subjected to RT-PCR analysis of NCYM RNA or the negative control U1 RNA. Error bars represent standard errors. "p<0.01.

**Figure 4.** BET bromodomain inhibitors reduce NCYM gene expression. (A) BE(2)-C and Kelly cells were treated with vehicle control or 1 µM JQ1 for 48 h, followed by RNA extraction and real-time RT-PCR analysis of NCYM expression. (B) BE(2)-C and Kelly cells were treated with vehicle control or 1 µM I-BET151 for 48 h followed by RNA extraction and real-time RT-PCR analysis of NCYM expression.
Figure 5. NCYM expression in neuroblastoma tissues positively correlates with N-Myc, NonO and IncUSMycN expression and poor patient prognoses. (A-C) Two-sided Pearson’s correlation was used to analyze correlation between NCYM expression and N-Myc (A), NonO (B) and IncUSMycN (C) expression in tumor tissues from 88 and 476 neuroblastoma patients in the publicly available microarray gene expression Versteeg dataset and Kocak dataset, respectively. (D) Kaplan-Meier curves showed the probability of overall survival of patients according to the levels of NCYM expression in the 88 and 476 neuroblastoma patients in the Versteeg and Kocak datasets, respectively.
NCYM RNA binds to the RNA-binding protein NonO. We have previously shown that the RNA-binding protein NonO upregulates N-Myc mRNA expression (14). Next we performed RNA immunoprecipitation assays with an anti-NonO antibody or control IgG, followed by RT-PCR analysis of NCYM RNA. As shown in Fig. 3, the anti-NonO antibody, compared with the control IgG, efficiently immunoprecipitated NCYM RNA, compared with the negative control U1 RNA. The data suggest that NCYM RNA forms a complex with NonO protein, leading to N-Myc mRNA upregulation.

BET bromodomain inhibitors reduce NCYM gene expression. The BET bromodomain inhibitors JQ1 and I-BET151 have been shown to reduce oncogene expression (25,26). We next examined whether the BET bromodomain inhibitors modulated NCYM expression. BE(2)-C and Kelly cells were treated with vehicle control or the BET bromodomain inhibitor JQ1 or I-BET151. RT-PCR analysis showed that treatment with JQ1 (Fig. 4A) or I-BET151 (Fig. 4B) reduced NCYM RNA expression in both BE(2)-C and Kelly cells. The data suggest that NCYM gene expression is regulated by BET bromodomain proteins, and that BET bromodomain inhibitors can be employed to suppress NCYM expression.

NCYM expression in neuroblastoma tissues positively correlates with N-Myc, NonO and IncUSMycN expression and poor patient prognoses. We finally examined correlation of NCYM expression in human neuroblastoma tissues with N-Myc, NonO and IncUSMycN expression and patient prognosis, using the publicly available (http://r2.amc.nl) Versteeg and Kocak (21,22) microarray gene expression datasets. Probes for NCYM, N-Myc, NonO and IncUSMycN in the Affymetrix HG-U133_Plus_2 microarray in the Versteeg dataset were 207028_at, 209757_s_at, 200057_s_at and 244438_at, respectively. Probes for NCYM, N-Myc, NonO and IncUSMycN in the Agilent Technologies oligonucleotide microarrays in the Kocak dataset were UKv4_A_23_P67952, UKv4_A_24_P94402, UKv4_A_24_P151727 and UKv4_A_24_P486173, respectively. As shown in Fig. 5A-C, NCYM RNA expression was positively correlated with N-Myc, NonO and IncUSMycN in the cohorts of 88 and 476 neuroblastoma patients, respectively. Kaplan-Meier analysis showed that high levels of NCYM expression in neuroblastoma tissues correlated with poor patient prognoses (Fig. 5D). Taken together, the data suggest that high levels of NCYM expression in human neuroblastoma tissues positively correlate with N-Myc, NonO and IncUSMycN expression and predict poor patient survival.

Discussion

The MYCN antisense gene NCYM, like the MYCN and the long non-coding RNA IncUSMYCN genes, is amplified in approximately a quarter of human neuroblastoma tissues (15). Long non-coding RNAs are now well-known to exert biological effects through both transcriptional and post-transcriptional mechanisms and to regulate gene transcription both in cis and in trans (24,27). We have recently reported that the long non-coding RNA IncUSMycN upregulates N-Myc mRNA expression by binding to the RNA-binding protein NonO, but does not directly regulate MYCN gene transcription since knocking down IncUSMycN expression does not have an effect on histone H3K4 trimethylation, a marker for active gene transcription, at the MYCN gene promoter (14). In this study, we found that IncUSMycN upregulates NCYM expression in human neuroblastoma cells, and that knocking down IncUSMycN expression reduces histone H3K4 trimethylation at the NCYM gene promoter. The data suggest that IncUSMycN upregulates NCYM expression by activating its gene transcription.

This study demonstrates that NCYM upregulates N-Myc mRNA and protein expression, and that NCYM RNA binds to the RNA-binding protein NonO. As our previous study shows that NonO protein binds to N-Myc mRNA and post-transcriptionally upregulates N-Myc mRNA expression (14), we propose that NCYM RNA upregulates N-Myc mRNA expression by binding to NonO protein. In addition, we have confirmed that knocking down NCYM expression leads to neuroblastoma cell growth inhibition. Taken together, the data suggest that NCYM RNA overexpression upregulates N-Myc mRNA expression by binding to NonO protein, leading to neuroblastoma cell proliferation.

This study shows that high levels of NCYM expression in two independent cohorts of human neuroblastoma tissues positively correlate with high levels of N-Myc, NonO and IncUSMycN expression. Importantly, Kaplan-Meier analysis shows that high levels of NCYM expression in neuroblastoma tissues correlate with poor prognosis in the two cohorts of 88 and 476 patients. These data therefore demonstrate that high levels of NCYM expression in human neuroblastoma tissues can be employed as a marker for poor prognosis and a therapeutic target.

Histone lysine acetylation plays a pivotal role in regulating chromatin dynamics and gene transcription. The BET bromodomain is a conserved structural unit in chromatin-associated proteins and histone acetyltransferases, known to recognize acetyl-lysine residues on proteins (28). BET bromodomain inhibitors have been shown to exert anticancer effects against neuroblastoma by blocking BET bromodomain protein binding to the MYCN gene intron 1, a region shared by the NCYM and the MYCN genes, and consequently reducing N-Myc expression (17,26). In this study, we found that suppression of BET bromodomain proteins by the BET bromodomain inhibitors JQ1 and I-BET151 considerably reduces NCYM expression, and that knocking down NCYM expression with siRNAs considerably reduces neuroblastoma cell proliferation. Our data suggest that BET bromodomain inhibitors reduce N-Myc expression directly by repressing MYCN gene transcription and indirectly by repressing NCYM gene transcription, and exert anticancer effects against neuroblastoma by simultaneously blocking the expression of N-Myc and NCYM.

In conclusion, NCYM, MYCN and IncUSMycN genes are co-amplified in human neuroblastoma. Our data demonstrate that the long non-coding RNA IncUSMycN upregulates NCYM expression by activating its gene transcription, and that NCYM RNA upregulates N-Myc expression by binding to the RNA-binding protein NonO. High levels of NCYM expression in human neuroblastoma tissues correlate with
high levels of N-Myc, NonO and IncUSMYCN expression and poor patient survival, and treatment with BET bromodomain inhibitors reduces NCYM expression. Our findings therefore provide further evidence for the application of BET bromodomain inhibitors for the therapy of neuroblastoma characterized by MYCN/NCYM gene locus amplification.

Acknowledgements

This study was supported by National Health and Medical Research Council (NHMRC) Australia grants. T.L. is a recipient of an Australian Research Council Future Fellowship. Children's Cancer Institute Australia is affiliated with UNSW Australia and Sydney Children's Hospital.

References